Suppr超能文献

在去势抵抗性前列腺癌中,组蛋白去乙酰化酶6(HDAC6)通过调节热休克蛋白90(Hsp90)的乙酰化来调控雄激素受体的超敏反应和核定位。

HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.

作者信息

Ai Junkui, Wang Yujuan, Dar Javid A, Liu June, Liu Lingqi, Nelson Joel B, Wang Zhou

机构信息

Department of Urology, University of Pittsburgh School of Medicine, Pennsylvania 15232, USA.

出版信息

Mol Endocrinol. 2009 Dec;23(12):1963-72. doi: 10.1210/me.2009-0188. Epub 2009 Oct 23.

Abstract

The development of castration-resistant prostate cancer (PCa) requires that under castration conditions, the androgen receptor (AR) remains active and thus nuclear. Heat shock protein 90 (Hsp90) plays a key role in androgen-induced and -independent nuclear localization and activation of AR. Histone deacetylase 6 (HDAC6) is implicated, but has not been proven, in regulating AR activity via modulating Hsp90 acetylation. Here, we report that knockdown of HDAC6 in C4-2 cells using short hairpin RNA impaired ligand-independent nuclear localization of endogenous AR and inhibited PSA expression and cell growth in the absence or presence of dihydrotestosterone (DHT). The dose-response curve of DHT-stimulated C4-2 colony formation was shifted by shHDAC6 such that approximately 10-fold higher concentration of DHT is required, indicating a requirement for HDAC6 in AR hypersensitivity. HDAC6 knockdown also inhibited C4-2 xenograft tumor establishment in castrated, but not in testes-intact, nude mice. Studies using HDAC6-deficient mouse embryonic fibroblasts cells showed that inhibition of AR nuclear localization by HDAC6 knockdown can be largely alleviated by expressing a deacetylation mimic Hsp90 mutant. Taken together, our studies suggest that HDAC6 regulates AR hypersensitivity and nuclear localization, mainly via modulating HSP90 acetylation. Targeting HDAC6 alone or in combination with other therapeutic approaches is a promising new strategy for prevention and/or treatment of castration-resistant PCa.

摘要

去势抵抗性前列腺癌(PCa)的发展要求在去势条件下,雄激素受体(AR)保持活性并因此定位于细胞核。热休克蛋白90(Hsp90)在雄激素诱导的和非依赖性的AR细胞核定位及激活中起关键作用。组蛋白去乙酰化酶6(HDAC6)与通过调节Hsp90乙酰化来调控AR活性有关,但尚未得到证实。在此,我们报道,使用短发夹RNA敲低C4-2细胞中的HDAC6会损害内源性AR的非配体依赖性细胞核定位,并在不存在或存在二氢睾酮(DHT)的情况下抑制前列腺特异性抗原(PSA)表达和细胞生长。shHDAC6使DHT刺激的C4-2集落形成的剂量反应曲线发生偏移,以至于需要大约高10倍浓度的DHT,这表明AR超敏反应需要HDAC6。敲低HDAC6也抑制了去势裸鼠而非睾丸完整裸鼠中C4-2异种移植瘤的形成。使用HDAC6缺陷型小鼠胚胎成纤维细胞的研究表明,通过表达去乙酰化模拟Hsp90突变体,可在很大程度上缓解敲低HDAC6对AR细胞核定位的抑制作用。综上所述,我们的研究表明,HDAC6主要通过调节HSP90乙酰化来调控AR超敏反应和细胞核定位。单独靶向HDAC6或与其他治疗方法联合使用是预防和/或治疗去势抵抗性PCa的一种有前景的新策略。

相似文献

6
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
Bioorg Med Chem Lett. 2016 Nov 1;26(21):5222-5228. doi: 10.1016/j.bmcl.2016.09.058. Epub 2016 Oct 4.

引用本文的文献

5
The role of protein acetylation in carcinogenesis and targeted drug discovery.蛋白质乙酰化在致癌作用和靶向药物发现中的作用。
Front Endocrinol (Lausanne). 2022 Sep 12;13:972312. doi: 10.3389/fendo.2022.972312. eCollection 2022.
9
Epigenetic Editing in Prostate Cancer: Challenges and Opportunities.前列腺癌中的表观遗传编辑:挑战与机遇
Epigenetics. 2022 May;17(5):564-588. doi: 10.1080/15592294.2021.1939477. Epub 2021 Jun 15.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验